- Home
- AXR vs SLS Comparison
AXR vs SLS Comparison
Compare AXR & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXR
- SLS
- Stock Information
- Founded
- AXR 1961
- SLS 2012
- Country
- AXR United States
- SLS United States
- Employees
- AXR N/A
- SLS N/A
- Industry
- AXR Homebuilding
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- AXR Real Estate
- SLS Health Care
- Exchange
- AXR Nasdaq
- SLS Nasdaq
- Market Cap
- AXR 110.0M
- SLS 89.6M
- IPO Year
- AXR N/A
- SLS N/A
- Fundamental
- Price
- AXR $20.13
- SLS $1.08
- Analyst Decision
- AXR
- SLS
- Analyst Count
- AXR 0
- SLS 0
- Target Price
- AXR N/A
- SLS N/A
- AVG Volume (30 Days)
- AXR 19.7K
- SLS 864.9K
- Earning Date
- AXR 03-07-2025
- SLS 03-20-2025
- Dividend Yield
- AXR N/A
- SLS N/A
- EPS Growth
- AXR 472.07
- SLS N/A
- EPS
- AXR 2.41
- SLS N/A
- Revenue
- AXR $58,052,000.00
- SLS N/A
- Revenue This Year
- AXR N/A
- SLS N/A
- Revenue Next Year
- AXR N/A
- SLS N/A
- P/E Ratio
- AXR $8.20
- SLS N/A
- Revenue Growth
- AXR 30.35
- SLS N/A
- 52 Week Low
- AXR $15.88
- SLS $0.77
- 52 Week High
- AXR $39.67
- SLS $1.84
- Technical
- Relative Strength Index (RSI)
- AXR 33.34
- SLS 39.25
- Support Level
- AXR $19.67
- SLS $1.13
- Resistance Level
- AXR $20.71
- SLS $1.25
- Average True Range (ATR)
- AXR 0.97
- SLS 0.07
- MACD
- AXR 0.16
- SLS -0.01
- Stochastic Oscillator
- AXR 32.58
- SLS 13.04
About AXR AMREP Corporation
Amrep Corp through its subsidiaries is engaged in the Real estate business. Its activities include land sales and lease activities, which involve the obtaining of approvals and the sale of both developed and undeveloped lots to homebuilders, commercial users, and others, as well as investments in commercial and investment properties. Its operating segments include Land development and Homebuilding. The firm generates a majority of its revenue from the Land development segment. Geographically, all the activities are carried out throughout the United States.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.